Literature DB >> 28118809

Involvement of protoporphyrin IX accumulation in the pathogenesis of isoniazid/rifampicin-induced liver injury: the prevention of curcumin.

Leiyan He1,2, Yaoxue Guo1,2, Ye Deng1,2, Chun Li1,2, Chengzi Zuo1, Wenxing Peng1.   

Abstract

Combination of isoniazid (INH) and rifampicin (RFP) causes liver injury frequently among tuberculosis patients. However, mechanisms of the hepatotoxicity are not entirely understood. Protoporphyrin IX (PPIX) accumulation, as an endogenous hepatotoxin, resulting from isoniazid and rifampicin co-therapy (INH/RFP) has been reported in PXR-humanized mice. Aminolevulinic acid synthase1 (ALAS1), ferrochelatase (FECH) and breast cancer resistance protein (BCRP) play crucial roles in PPIX synthesis, metabolism and transport, respectively. Herein, this study focused on the role of INH/RFP in these processes. We observed PPIX accumulation in human hepatocytes (L-02) and mouse livers. FECH expression was initially found downregulated both in L-02 cells and mouse livers and expression levels of ALAS1 and BCRP were elevated in L-02 cells after INH/RFP treatment, indicating FECH inhibition and ALAS1 induction might confer a synergistic effect on PPIX accumulation. Additionally, our results revealed that curcumin alleviated INH/RFP-induced liver injury, declined PPIX levels and induced FECH expression in both L-02 cells and mice. In conclusion, our data provide a novel insight in the mechanism of INH/RFP-induced PPIX accumulation and evidence for understanding pathogenesis of INH/RFP-induced liver injury, and suggest that amelioration of PPIX accumulation might be involved in the protective effect of curcumin on INH/RFP-induced liver injury.

Entities:  

Keywords:  Antitubercular drugs; curcumin; drug-induced liver injury; heme precursor; hepatotoxicity; isoniazid; protoporphyrin IX; rifampicin

Mesh:

Substances:

Year:  2017        PMID: 28118809     DOI: 10.3109/00498254.2016.1160159

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  5 in total

1.  Curcumin inhibits the growth of liver cancer stem cells through the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin signaling pathway.

Authors:  Ji Wang; Chunying Wang; Gaofeng Bu
Journal:  Exp Ther Med       Date:  2018-01-29       Impact factor: 2.447

2.  Genetic Variations Associated with Anti-Tuberculosis Drug-Induced Liver Injury.

Authors:  Yifan Bao; Xiaochao Ma; Theodore P Rasmussen; Xiao-Bo Zhong
Journal:  Curr Pharmacol Rep       Date:  2018-03-15

3.  NR1I2 genetic polymorphisms and the risk of anti-tuberculosis drug-induced hepatotoxicity: A systematic review and meta-analysis.

Authors:  Miaomiao Yang; Yunliang Qiu; Yanyu Jin; Wenpei Liu; Qingliang Wang; Honggang Yi; Shaowen Tang
Journal:  Pharmacol Res Perspect       Date:  2020-12

4.  Genetic and Functional Evaluation of the Role of FOXO1 in Antituberculosis Drug-Induced Hepatotoxicity.

Authors:  Jingwei Zhang; Lin Jiao; Jiajia Song; Tao Wu; Hao Bai; Tangyuheng Liu; Zhenzhen Zhao; Xuejiao Hu; Binwu Ying
Journal:  Evid Based Complement Alternat Med       Date:  2021-06-19       Impact factor: 2.629

Review 5.  Therapeutic Potential of Curcumin as an Antimycobacterial Agent.

Authors:  Nilakshi Barua; Alak Kumar Buragohain
Journal:  Biomolecules       Date:  2021-08-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.